Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 44kWORD 9k
6 January 2021
Priority question for written answer  P-000047/2021
to the Commission
Rule 138
Vilija Blinkevičiūtė (S&D)
 Subject: Distribution of COVID-19 vaccines and the vaccination procedure in the Member States

The Commission already started purchasing vaccines in June 2020, and it has committed to ensuring the necessary distribution of vaccine stocks in the Member States. However, it is clear that this process is foundering in the EU in light of the challenges affecting the Member States.

BioNTech and Pfizer had placed no more than 12 million vaccine doses on the EU market by the end of 2020, despite the commitments they had made. As a result, Member States are not able to obtain sufficient vaccine doses. For example, Lithuania received only 20 000 vaccine doses. In addition, some Member States have not yet started vaccinating the population at all.

The EU is currently far behind the United States, the United Kingdom and Israel, both in purchasing vaccines and in vaccinating people. This is not a sign of good governance when third countries are able to procure vaccines much more efficiently and vaccinate people effectively.

Can the Commission answer the following questions:

1. What bureaucratic or other problems resulted in the EU failing thus far to secure the necessary quantities of vaccines? What is the role of the European Medicines Agency in purchasing vaccines? Does the EU have a common and coordinated approach in respect of how people will be vaccinated and who will be given priority?

2. How does the Commission intend to ensure that the purchase of vaccines is coordinated and that the Member States receive the required doses of vaccine?

Original language of question: LT
Last updated: 11 January 2021Legal notice - Privacy policy